1887
Research article Open Access
Like 0

Abstract

Introduction

Seasonal influenza vaccination is widely recommended for people with risk factors, especially for people who are elderly. However, influenza vaccine effectiveness (IVE) varies year after year because of the variable antigenic composition of the circulating viruses and the vaccine composition. We summarise the results of IVE and the impact of previous vaccination among subjects 60 years of age and over in a multicentre prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and Respiratory Viruses Disease (VAHNSI) in Spain. We applied the test-negative design taking laboratory-confirmed influenza as outcome and vaccination status as exposure. Information about potential confounders was obtained from clinical registries or directly from patients. Adjusted IVE was 19% (95% confidence interval (CI): −15 to 43). For patients vaccinated in the current season but not in the two previous seasons, effectiveness was 49% (95% CI: −20 to 78) and for patients vaccinated in the current and any of two previous seasons, effectiveness was 29% (95% CI: −3 to 52). For those patients not vaccinated in the current season but vaccinated in any of the two previous seasons, effectiveness was 53% (95% CI: 8 to 76). Our data show a low vaccine effectiveness for the 2016/17 influenza season.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2018.23.8.17-00318
2018-02-22
2018-06-19
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2018.23.8.17-00318
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/23/8/eurosurv-23-8-2.html?itemId=/content/10.2807/1560-7917.ES.2018.23.8.17-00318&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec. 2012;87(47):461-76. PMID: 23210147 
  2. Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P, et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine. 2002;20(Suppl 5):B50-4.  https://doi.org/10.1016/S0264-410X(02)00507-8  PMID: 12477420 
  3. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis. 1998;178(1):53-60.  https://doi.org/10.1086/515616  PMID: 9652423 
  4. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165(3):265-72.  https://doi.org/10.1001/archinte.165.3.265  PMID: 15710788 
  5. Council of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. Official Journal of the European Union. Luxembourg: Publications Office of the European Union; 2009. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=CELEX:32009H1019&from=EN
  6. Puig-Barberà J, Arnedo-Pena A, Pardo-Serrano F, Tirado-Balaguer MD, Pérez-Vilar S, Silvestre-Silvestre E, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case-control study. Vaccine. 2010;28(47):7460-7.  https://doi.org/10.1016/j.vaccine.2010.09.042  PMID: 20875486 
  7. Puig-Barberà J, García-de-Lomas J, Díez-Domingo J, Arnedo-Pena A, Ruiz-García M, Limón-Ramírez R, et al. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS One. 2014;9(11):e112294.  https://doi.org/10.1371/journal.pone.0112294  PMID: 25392931 
  8. Puig-Barberà J, Mira-Iglesias A, Tortajada-Girbés M, Lopez-Labrador FX, Belenguer-Varea A, Carballido-Fernandez M, et al. Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results. Euro Surveill. 2015;20(8):21044.  https://doi.org/10.2807/1560-7917.ES2015.20.8.21044  PMID: 25742432 
  9. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Wkly Epidemiol Rec. 2016;91(10):121-32. PMID: 26971356 
  10. European Centre for Disease Prevention and Control (ECDC). Risk assessment of seasonal influenza, EU/EEA, 2016/2017, 24 December 2016. Stockholm: ECDC; 26 Dec 2016. Available from: https://ecdc.europa.eu/en/publications-data/risk-assessment-seasonal-influenza-eueea-20162017-24-december-2016
  11. The Francis Crick Institute. Reported prepared for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2017-2018. London: The Francis Crick Institute;2017. Available from: https://www.crick.ac.uk/media/358671/crick_nh_vcm_report_feb_2017_v2.pdf
  12. Castilla J, Navascués A, Casado I, Díaz-González J, Pérez-García A, Fernandino L, et al. Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis. Euro Surveill. 2017;22(7):30465.  https://doi.org/10.2807/1560-7917.ES.2017.22.7.30465  PMID: 28230523 
  13. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, et al. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013;56(10):1363-9.  https://doi.org/10.1093/cid/cit060  PMID: 23413420 
  14. Zhang L, Yang P, Thompson MG, Pan Y, Ma C, Wu S, et al. Influenza vaccine effectiveness in preventing influenza illness among children during school-based outbreaks in the 2014-2015 season in Beijing, China. Pediatr Infect Dis J. 2017;36(3):e69-75.  https://doi.org/10.1097/INF.0000000000001434  PMID: 27902651 
  15. McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014;59(10):1375-85.  https://doi.org/10.1093/cid/ciu680  PMID: 25270645 
  16. Rondy M, Launay O, Castilla J, Costanzo S, Puig-Barberà J, Gefenaite G, et al. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. Vaccine. 2017;35(34):4298-306.  https://doi.org/10.1016/j.vaccine.2017.06.088  PMID: 28709555 
  17. Puig-Barberà J, Natividad-Sancho A, Calabuig-Pérez J, Lluch-Rodrigo JA, Pastor-Villalba E, Martínez-Úbeda S, et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine. 2013;31(37):3995-4002.  https://doi.org/10.1016/j.vaccine.2013.05.070  PMID: 23731629 
  18. World Health Organization (WHO). WHO information for molecular diagnosis of influenza virus in humans - update. Geneva: WHO; Nov 2012. [Accessed 12 Feb 2018]. Available from: http://www.who.int/influenza/gisrs_laboratory/molecular_diagnosis_influenza_virus_humans_update_201211.pdf
  19. He J, Bose ME, Beck ET, Fan J, Tiwari S, Metallo J, et al. Rapid multiplex reverse transcription-PCR typing of influenza A and B virus, and subtyping of influenza A virus into H1, 2, 3, 5, 7, 9, N1 (human), N1 (animal), N2, and N7, including typing of novel swine origin influenza A (H1N1) virus, during the 2009 outbreak in Milwaukee, Wisconsin. J Clin Microbiol. 2009;47(9):2772-8.  https://doi.org/10.1128/JCM.00998-09  PMID: 19641063 
  20. Suwannakarn K, Payungporn S, Chieochansin T, Samransamruajkit R, Amonsin A, Songserm T, et al. Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assays. J Virol Methods. 2008;152(1-2):25-31.  https://doi.org/10.1016/j.jviromet.2008.06.002  PMID: 18598722 
  21. World Health Organization (WHO). WHO molecular diagnosis of influenza virus in humans - update. Geneva: WHO; Aug 2011. [Accessed Feb 2018]. Available from: http://www.who.int/influenza/resources/documents/molecular_diagnosis_influenza_virus_humans_update_201108.pdf
  22. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307-21.  https://doi.org/10.1093/sysbio/syq010  PMID: 20525638 
  23. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8.  https://doi.org/10.1016/j.vaccine.2013.02.053  PMID: 23499601 
  24. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91.  https://doi.org/10.1586/14760584.2014.966695  PMID: 25348015 
  25. Galobardes B, Shaw M, Lawlor DA, Lynch JW, Davey Smith G. Indicators of socioeconomic position (part 2). J Epidemiol Community Health. 2006;60(2):95-101.  https://doi.org/10.1136/jech.2004.028092  PMID: 16415256 
  26. Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, et al. Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017. Euro Surveill. 2017;22(6):30460.  https://doi.org/10.2807/1560-7917.ES.2017.22.6.30460  PMID: 28205503 
  27. Flannery B, Chung JR, Thaker SN, Monto AS, Martin ET, Belongia EA, et al. Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(6):167-71.  https://doi.org/10.15585/mmwr.mm6606a3  PMID: 28207689 
  28. Kissling E, Rondy MI-MOVE/I-MOVE+ study team. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. Euro Surveill. 2017;22(7):30464.  https://doi.org/10.2807/1560-7917.ES.2017.22.7.30464  PMID: 28230524 
  29. Harvala H, Frampton D, Grant P, Raffle J, Ferns RB, Kozlakidis Z, et al. Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017. Euro Surveill. 2017;22(8):30466.  https://doi.org/10.2807/1560-7917.ES.2017.22.8.30466  PMID: 28251889 
  30. Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, et al. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010-11 to 2014-15. J Infect Dis. 2017;215(7):1059-99.  https://doi.org/10.1093/infdis/jix074  PMID: 28180277 
  31. Katz JM, Hancock K, Xu X. Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther. 2011;9(6):669-83.  https://doi.org/10.1586/eri.11.51  PMID: 21692672 
  32. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, et al. A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-2015 season. Clin Infect Dis. 2016;63(1):21-32.  https://doi.org/10.1093/cid/ciw176  PMID: 27025838 
  33. Ellis PD. The Essential Guide to Effect Sizes: Statistical Power, Meta-Analysis, and the Interpretation of Research Results. Cambridge: Cambridge University Press; 2010.
  34. Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter A-L, Hickman R, et al. Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018. Euro Surveill. 2018;23(5):18-00035.  https://doi.org/10.2807/1560-7917.ES.2018.23.5.18-00035  PMID: 29409570 
/content/10.2807/1560-7917.ES.2018.23.8.17-00318
Loading

Data & Media loading...

Supplementary data

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error